Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

02:24 EST 20th November 2017 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 14,000+

Extremely Relevant

Bevacizumab and colorectal cancer in geriatrics

Thomas Aparicio talks to ecancer at SIOG 2017 in Warsaw. He discusses elderly patients with colorectal cancer and the best treatments.  Dr Aparicio the trails with bevacizumab, and the successes and concerns of this therapy.  One of these issues is...


[Articles] TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

TAS-102 plus bevacizumab has promising activity with manageable safety, suggesting that this combination might become a potential treatment option for patients with metastatic colorectal cancer in a refractory setting.

Clinical advances in treating colorectal cancer

Prof Geißler speaks with ecancer at ESMO 2017 about recent trials in treating colorectal cancer presented at the congress. He notes the Prodige 18 trial of bevacizumab and the Tricolore trial of combination therapy as stand-out presentations. Prof...


Cetuximab vs. Bevacizumab for KRAS Wild-Type Advanced Colorectal Cancer

Survival was similar with either agent when combined with first-line chemotherapy.

[Comment] New perspectives for TAS-102: TASK successful?

The US Food and Drug Administration and European Medicines Agency have granted approval to TAS-102 for the treatment of refractory metastatic colorectal cancer.1,2 In The Lancet Oncology, Yasutoshi Kuboki and colleagues report on the results of C-TASK FORCE,3 a phase 1/2 study on the combination of TAS-102 with bevacizumab. The rationale for this study was sound and strong. Phosphorylated trifluri...

[Articles] Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

The benefit conferred by incorporation of bevacizumab is sustained with extended follow-up as evidenced by the overall survival curves remaining separated. After progression while receiving bevacizumab, we did not observe a negative rebound effect (ie, shorter survival after bevacizumab is stopped than after chemotherapy alone is stopped). These findings represent proof-of-concept of the efficacy ...

Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer

-- The VENTANA MMR IHC Panel1 helps differentiate between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer -- The National Comprehensive Cancer Networ...

Bevacizumab improves survival in NSCLC patients

In what could be good news for recently approved bevacizumab biosimilar Mvasi, a study has shown that bevacizumab-containing regimens improve survival in advanced non-squamous non–small cell lung cancer (NSCLC) patients.

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

Relevant

Roche Receives FDA Clearance for the VENTANA MMR IHC Panel for Patients Diagnosed With Colorectal...

The tests detect certain proteins associated with a DNA repair mechanism called MMR, and aid in differentiating between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer.

FDA Approves Amgen and Allergan’s Mvasi for the Treatment of Five Types of Cancer

THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved...

First biosimilar to treat cancer approved by FDA

The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) as a biosimilar to the cancer treatment Avastin (bevacizumab). This represents the first biosimilar approved by the regulatory body for cancer treatment.

FDA approves first-ever biosimilar for cancer treatment

The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer in the US – Amgen’s Mvasi (bevacizumab-awwb), a biologic version of Genetech’s Avastin (bevacizumab). The drug is approved as a therapy for colon, lung, brain, kidney and cervical cancers. These include: read more

US FDA approves Mvasi for treatment of five types of cancer

Amgen and Allergan have announced that the US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab─awwb) for all eligible indications of the reference product, Avastin (bevacizumab).

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin

September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the...

FDA OKs First 'Biosimilar' Drug to Fight Cancer

THURSDAY, Sept. 14, 2017 -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of...

A Blueprint to Advance Colorectal Cancer Immunotherapies

Fight Colorectal Cancer (Fight CRC) and the Cancer Research Institute (CRI), have announced “A Blueprint to Advance Colorectal Cancer Immunotherapies” is published in the journal Cancer Immunology Research. The article is the culmination of an over...

First Oncology Biosimilar Approved in US: Bevacizumab

The FDA has approved the first biosimilar for use in the treatment of cancer: Myasi, or bevacizumab-awwb (equivalent to Avastin). News Alerts

Possible Breakthrough in Colorectal Cancer Drug Development Cited

NewsStemSynergy announces breakthrough in colorectal cancer drug development. Scientists showed that a novel class of Wnt inhibitors, CK1alpha agonists, blocked colorectal cancer growth with minimal gastrointestinal toxicity.

Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an analysis of a large, randomized clinical trial.

Colorectal cancer death rates rising in people under 55

(American Cancer Society) A new report finds that colorectal cancer mortality rates have increased in adults under 55 since the mid-2000s after falling for decades.

Streptococcus Gallolyticus Spurs Colorectal Tumor Growth in Mice – The Scientist

The ScientistStreptococcus Gallolyticus Spurs Colorectal Tumor Growth in MiceThe ScientistBRYAN SATALINOScientists have long known of the link between the bacteria Streptococcus gallolyticus and colorectal cancer (CRC) in humans—numerous case studies have reported instances of patients with S. gallolyticus infections who also have CRC.Bacterium promotes colorectal tumor growthMedical News TodayB...

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

FDA OKs First 'Biosimilar' Drug to Fight Cancer, Mvasi

THURSDAY, Sept. 14, 2017 -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of...

Nationwide Colorectal Screening in New Zealand

Dr Melissa McLeod and Professor Tony Blakely Nationwide Colorectal Screening in New Zealand: a tricky balance of improving overall population health and addressing inequalities In this blog we will discuss a paper recently published in Cancer Epidemiology Biomarkers and Prevention [1] by the BODE3 team, which modelled a nationwide colorectal cancer (CRC) screening programme for […] The post ...


Quick Search
Advertisement
 

News Quicklinks